159 related articles for article (PubMed ID: 38461087)
1. [Targeting the spliceosome: A new therapeutic strategy to counteract chemotherapy resistance in lung cancer?].
Shreim A; Gazzeri S; Eymin B
Rev Mal Respir; 2024 Apr; 41(4):294-298. PubMed ID: 38461087
[TBL] [Abstract][Full Text] [Related]
2. Biology of the mRNA Splicing Machinery and Its Dysregulation in Cancer Providing Therapeutic Opportunities.
Blijlevens M; Li J; van Beusechem VW
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34065983
[TBL] [Abstract][Full Text] [Related]
3. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
4. Targeting the spliceosome machinery: A new therapeutic axis in cancer?
Eymin B
Biochem Pharmacol; 2021 Jul; 189():114039. PubMed ID: 32417188
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic Targeting of RNA Splicing in Cancer.
Bonner EA; Lee SC
Genes (Basel); 2023 Jun; 14(7):. PubMed ID: 37510283
[TBL] [Abstract][Full Text] [Related]
6. Targeting the deregulated spliceosome core machinery in cancer cells triggers mTOR blockade and autophagy.
Quidville V; Alsafadi S; Goubar A; Commo F; Scott V; Pioche-Durieu C; Girault I; Baconnais S; Le Cam E; Lazar V; Delaloge S; Saghatchian M; Pautier P; Morice P; Dessen P; Vagner S; André F
Cancer Res; 2013 Apr; 73(7):2247-58. PubMed ID: 23358685
[TBL] [Abstract][Full Text] [Related]
7. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
8. Roles of minor spliceosome in intron recognition and the convergence with the better understood major spliceosome.
Ding Z; Meng YR; Fan YJ; Xu YZ
Wiley Interdiscip Rev RNA; 2023 Jan; 14(1):e1761. PubMed ID: 36056453
[TBL] [Abstract][Full Text] [Related]
9. Emerging roles of spliceosome in cancer and immunity.
Yang H; Beutler B; Zhang D
Protein Cell; 2022 Aug; 13(8):559-579. PubMed ID: 34196950
[TBL] [Abstract][Full Text] [Related]
10. SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells.
Wang C; Zhou Z; Subhramanyam CS; Cao Q; Heng ZSL; Liu W; Fu X; Hu Q
Commun Biol; 2020 May; 3(1):268. PubMed ID: 32461560
[TBL] [Abstract][Full Text] [Related]
11. Processive phosphorylation of alternative splicing factor/splicing factor 2.
Aubol BE; Chakrabarti S; Ngo J; Shaffer J; Nolen B; Fu XD; Ghosh G; Adams JA
Proc Natl Acad Sci U S A; 2003 Oct; 100(22):12601-6. PubMed ID: 14555757
[TBL] [Abstract][Full Text] [Related]
12. Mobilization of a splicing factor through a nuclear kinase-kinase complex.
Aubol BE; Keshwani MM; Fattet L; Adams JA
Biochem J; 2018 Feb; 475(3):677-690. PubMed ID: 29335301
[TBL] [Abstract][Full Text] [Related]
13. UHMK1 is a novel splicing regulatory kinase.
Arfelli VC; Chang YC; Bagnoli JW; Kerbs P; Ciamponi FE; Paz LMDS; Pankivskyi S; de Matha Salone J; Maucuer A; Massirer KB; Enard W; Kuster B; Greif PA; Archangelo LF
J Biol Chem; 2023 Apr; 299(4):103041. PubMed ID: 36803961
[TBL] [Abstract][Full Text] [Related]
14. RNA splicing, cell signaling, and response to therapies.
Abou Faycal C; Gazzeri S; Eymin B
Curr Opin Oncol; 2016 Jan; 28(1):58-64. PubMed ID: 26575690
[TBL] [Abstract][Full Text] [Related]
15. Serine-Arginine Protein Kinase 1 (SRPK1) as a Prognostic Factor and Potential Therapeutic Target in Cancer: Current Evidence and Future Perspectives.
Nikas IP; Themistocleous SC; Paschou SA; Tsamis KI; Ryu HS
Cells; 2019 Dec; 9(1):. PubMed ID: 31861708
[TBL] [Abstract][Full Text] [Related]
16. SKIP is a component of the spliceosome linking alternative splicing and the circadian clock in Arabidopsis.
Wang X; Wu F; Xie Q; Wang H; Wang Y; Yue Y; Gahura O; Ma S; Liu L; Cao Y; Jiao Y; Puta F; McClung CR; Xu X; Ma L
Plant Cell; 2012 Aug; 24(8):3278-95. PubMed ID: 22942380
[TBL] [Abstract][Full Text] [Related]
17. PRP4KA, a Putative Spliceosomal Protein Kinase, Is Important for Alternative Splicing and Development in
Kanno T; Venhuizen P; Wen TN; Lin WD; Chiou P; Kalyna M; Matzke AJM; Matzke M
Genetics; 2018 Dec; 210(4):1267-1285. PubMed ID: 30297453
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma.
Huang HH; Ferguson ID; Thornton AM; Bastola P; Lam C; Lin YT; Choudhry P; Mariano MC; Marcoulis MD; Teo CF; Malato J; Phojanakong PJ; Martin TG; Wolf JL; Wong SW; Shah N; Hann B; Brooks AN; Wiita AP
Nat Commun; 2020 Apr; 11(1):1931. PubMed ID: 32321912
[TBL] [Abstract][Full Text] [Related]
19. Regulation of chemoresistance via alternative messenger RNA splicing.
Eblen ST
Biochem Pharmacol; 2012 Apr; 83(8):1063-72. PubMed ID: 22248731
[TBL] [Abstract][Full Text] [Related]
20. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma.
Hayes GM; Carrigan PE; Beck AM; Miller LJ
Cancer Res; 2006 Apr; 66(7):3819-27. PubMed ID: 16585209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
